We noted that the IL-2 response at day 9 was only modest against these leukemia targets, but given strong responses against neuroblastoma and strong IL-2 response by fourth rechallenge, the TE9 binder was therefore selected for further optimization of CAR-T function. Here, IL2 is linked to neuroblastoma.